The role of statins in chronic kidney disease (CKD): Friend or foe?

Pharmacology and Therapeutics

Volumn 122, Issue 3, 2009, Pages 312-323

  Kassimatis, Theodoros I ^a   Konstantinopoulos, Panagiotis A ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease (CVD); Chronic kidney disease (CKD); Dyslipidemia; Isoprenylation; Pleiotropic effects; Statins

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN RECEPTOR; EZETIMIBE; FASUDIL; FLUINDOSTATIN; FOSINOPRIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RAC1 PROTEIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISOPRENYLATION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; MORBIDITY; MORTALITY; NONHUMAN; PATIENT SAFETY; PODOCYTE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STEM CELL; T LYMPHOCYTE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; SIGNAL TRANSDUCTION;

EID: 67349205850     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.03.008     Document Type: Review

References (191)

1. Aandahl E.M., Michaelsson J., Moretto W.J., Hecht F.M., and Nixon D.F. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78 5 (2004) 2454-2459
2. Agarwal R. Effects of statins on renal function. Am J Cardiol 97 5 (2006) 748-755
3. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 5 (2007) 409-418
4. Andreucci V.E., Fissell R.B., Bragg-Gresham J.L., Ethier J., Greenwood R., Pauly M., et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 44 5 Suppl 2 (2004) 61-67
5. Aprahamian T., Bonegio R., Rizzo J., Perlman H., Lefer D.J., Rifkin I.R., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 177 5 (2006) 3028-3034
6. Arnaud C., Braunersreuther V., and Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 15 6 (2005) 202-206
7. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12 (2007) 2957-2966
8. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 18 (2004) 2809-2816
9. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Symeonidis A.N., Pehlivanidis A.N., Bouloukos V.I., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57 7 (2004) 728-734
10. Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis E.O., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 4 (2002) 220-228
11. Attman P.O., and Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int Suppl 31 (1991) S16-23
12. Attman P.O., Alaupovic P., Tavella M., and Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11 1 (1996) 63-69
13. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
14. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210
15. Bernot D., Benoliel A.M., Peiretti F., Lopez S., Bonardo B., Bongrand P., et al. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol 41 2 (2003) 316-324
16. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., and Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63 1 (2003) 12-23
17. Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73 14 (1994) 3D-11D
18. Bottinger E.P., and Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 13 10 (2002) 2600-2610
19. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20 2 (2000) 556-562
20. Burridge K., and Wennerberg K. Rho and Rac take center stage. Cell 116 2 (2004) 167-179
21. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 5 (2004) 1062-1071
22. Chade A.R., Krier J.D., Textor S.C., Lerman A., and Lerman L.O. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol 17 12 (2006) 3394-3403
23. Chen C.L., Huang S.S., and Huang J.S. Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol 215 1 (2008) 223-233
24. Christensen M., Su A.W., Snyder R.W., Greco A., Lipschutz J.H., and Madaio M.P. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int 69 3 (2006) 457-463
25. Cohn J.N. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Ther 24 6 (2007) 1290-1304
26. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 9374 (2003) 2005-2016
27. Coresh J., Byrd-Holt D., Astor B.C., Briggs J.P., Eggers P.W., Lacher D.A., et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16 1 (2005) 180-188
28. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 17 (2007) 2038-2047
29. Coritsidis G., Rifici V., Gupta S., Rie J., Shan Z.H., Neugarten J., et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 39 5 (1991) 858-866
30. Cormack-Aboud F.C., Brinkkoetter P.T., Pippin J.W., Shankland S.J., and Durvasula R.V. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant (2008)
31. Coupel S., Leboeuf F., Boulday G., Soulillou J.P., and Charreau B. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 15 9 (2004) 2429-2439
32. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 6A (2007) 3C-18C
33. Descamps-Latscha B., Herbelin A., Nguyen A.T., Zingraff J., Jungers P., and Chatenoud L. Immune system dysregulation in uremia. Semin Nephrol 14 3 (1994) 253-260
34. Descamps-Latscha B., Jungers P., and Witko-Sarsat V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 20 5 (2002) 481-484
35. Deslypere J.P., Delanghe J., and Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet 336 8728 (1990) 1453
36. Diepeveen S.H., Wetzels J.F., Bilo H.J., van Tits L.J., and Stalenhoef A.F. Cholesterol in end-stage renal disease: the good, the bad or the ugly?. Neth J Med 66 2 (2008) 53-61
37. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145 2 (2006) 117-124
38. Eberlein M., Heusinger-Ribeiro J., and Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 133 7 (2001) 1172-1180
39. Epstein M., and Campese V.M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45 1 (2005) 2-14
40. Fassett R.G., Ball M.J., Robertson I.K., Geraghty D.P., and Coombes J.S. The Lipid lowering and Onset of Renal Disease (LORD) trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 9 (2008) 4
41. Fellstrom B.C., Holdaas H., and Jardine A.G. Why do we need a statin trial in hemodialysis patients?. Kidney Int Suppl 84 (2003) S204-S206
42. Feron O., Dessy C., Desager J.P., and Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 1 (2001) 113-118
43. Foley R.N., and Collins A.J. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 18 10 (2007) 2644-2648
44. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 1 (2001) 260-269
45. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 6736 (1999) 597-601
46. Gargalovic P., and Dory L. Caveolins and macrophage lipid metabolism. J Lipid Res 44 1 (2003) 11-21
47. Gelosa P., Cimino M., Pignieri A., Tremoli E., Guerrini U., and Sironi L. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 3 5 (2007) 567-577
48. Gojo A., Utsunomiya K., Taniguchi K., Yokota T., Ishizawa S., Kanazawa Y., et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568 1-3 (2007) 242-247
49. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 6257 (1990) 425-430
50. Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (in press). The double-edged sword of statin 935 immunomodulation. Int J Cardiol.
51. Graham K.L., Lee L.Y., Higgins J.P., Steinman L., Utz P.J., and Ho P.P. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 58 7 (2008) 2098-2104
52. Greenwood J., Walters C.E., Pryce G., Kanuga N., Beraud E., Baker D., et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17 8 (2003) 905-907
53. Grone H.J., Walli A., Grone E., Niedmann P., Thiery J., Seidel D., et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Lab Invest 60 3 (1989) 433-446
54. Grosser N., Erdmann K., Hemmerle A., Berndt G., Hinkelmann U., Smith G., et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun 325 3 (2004) 871-876
55. Gueler F., Park J.K., Rong S., Kirsch T., Lindschau C., Zheng W., et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170 4 (2007) 1192-1199
56. Guijarro C., Kasiske B.L., Kim Y., O'Donnell M.P., Lee H.S., and Keane W.F. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26 1 (1995) 152-161
57. Gupta S., Rifici V., Crowley S., Brownlee M., Shan Z., and Schlondorff D. Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int 41 5 (1992) 1161-1169
58. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 5350 (1998) 509-514
59. Hayashi K., Wakino S., Kanda T., Homma K., Sugano N., and Saruta T. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J Pharmacol Sci 100 1 (2006) 29-33
60. Hernandez-Perera O., Perez-Sala D., Soria E., and Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87 7 (2000) 616-622
61. Heusinger-Ribeiro J., Fischer B., and Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int 66 1 (2004) 187-195
62. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 9374 (2003) 2024-2031
63. Holvoet P., Donck J., Landeloos M., Brouwers E., Luijtens K., Arnout J., et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76 5 (1996) 663-669
64. Huber K., Christ G., Wojta J., and Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 103 Suppl 1 (2001) S7-S19
65. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H., et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21 12 (2001) 1896-1901
66. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 15 (1998) 1440-1445
67. Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8 1 (2006) 35-41 quiz 42-33
68. Jandeleit-Dahm K., Cao Z., Cox A.J., Kelly D.J., Gilbert R.E., and Cooper M.E. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 71 (1999) S31-36
69. Joles J.A. Statins and small GTPases: Koch's postulates and chronic kidney disease. Nephrol Dial Transplant 23 2 (2008) 433-438
70. Joles J.A., Kunter U., Janssen U., Kriz W., Rabelink T.J., Koomans H.A., et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11 4 (2000) 669-683
71. Joosten S.A., and Ottenhoff T.H. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 69 11 (2008) 760-770
72. Kamanna V.S., Pai R., Roh D.D., and Kirschenbaum M.A. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest 74 6 (1996) 1067-1079
73. Kasiske B.L., O'Donnell M.P., Cleary M.P., and Keane W.F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33 3 (1988) 667-672
74. Kasiske B.L., O'Donnell M.P., Schmitz P.G., Kim Y., and Keane W.F. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37 3 (1990) 880-891
75. Kassimatis T.I., Giannopoulou I., Koumoundourou D., Theodorakopoulou E., Varakis I., and Nakopoulou L. Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. J Cell Mol Med 10 4 (2006) 908-921
76. Kassimatis T.I., and Konstantinopoulos P.A. Statins in patients with chronic kidney disease: a double-edged sword?. J Am Coll Cardiol 52 20 (2008) 1679
77. Kato S., Chmielewski M., Honda H., Pecoits-Filho R., Matsuo S., Yuzawa Y., et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3 5 (2008) 1526-1533
78. Kaysen G.A., Gambertoglio J., Felts J., and Hutchison F.N. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 31 6 (1987) 1368-1376
79. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 2 Suppl 1 (2002) S1-S266
80. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. (2003). Am J Kidney Dis, 41(4 Suppl 3), I-IV, S1-91.
81. Khwaja A., Sharpe C.C., Noor M., and Hendry B.M. The role of geranylgeranylated proteins in human mesangial cell proliferation. Kidney Int 70 7 (2006) 1296-1304
82. Kim S.I., Han D.C., and Lee H.B. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11 1 (2000) 80-87
83. Kim S.I., Kim H.J., Han D.C., and Lee H.B. Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression. Kidney Int Suppl 77 (2000) S88-92
84. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6 7 (2007) 541-555
85. Konstantinopoulos P.A., and Papavassiliou A.G. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci 28 1 (2007) 6-13
86. Koren M.J., and Davidson M.H. ALLIANCE investigators. Impact of aggressive treatment with atorvastatin in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract 1070-123]. J Am Coll Cardiol 45 suppl A (2005) 391A
87. Koren M.J., and Hunninghake D.B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44 9 (2004) 1772-1779
88. Kramer S., Kron S., Wang-Rosenke Y., Loof T., Khadzhynov D., Morgera S., et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol 294 4 (2008) F801-811
89. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 9 (2000) 1004-1010
90. Kurusu A., Shou I., Nakamura S., Fukui M., Shirato I., and Tomino Y. Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 27 10 (2000) 767-770
91. Kuwahara N., Sasaki S., Kobara M., Nakata T., Tatsumi T., Irie H., et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol 123 2 (2008) 84-90
92. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6 12 (2000) 1399-1402
93. Kwan B.C., Beddhu S., Kronenberg F., and Cheung A.K. Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?. Nat Clin Pract Nephrol 2 2 (2006) 76-77
94. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 12 (1998) 1129-1135
95. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 37 (1998) 24266-24271
96. Law M.R., Wald N.J., and Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 308 6925 (1994) 367-372
97. Lee T.S., Chang C.C., Zhu Y., and Shyy J.Y. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110 10 (2004) 1296-1302
98. Lee T.S., and Chau L.Y. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8 3 (2002) 240-246
99. Li C., Lim S.W., Choi B.S., Lee S.H., Cha J.H., Kim I.S., et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25 6 (2005) 611-620
100. Liao J.K., Seto M., and Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50 1 (2007) 17-24
101. Liu Y., Coresh J., Eustace J.A., Longenecker J.C., Jaar B., Fink N.E., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 4 (2004) 451-459
102. London G.M., and Parfrey P.S. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 4 3 (1997) 194-211
103. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 16 5 (2005) 518-524
104. Manjunath G., Tighiouart H., Coresh J., Macleod B., Salem D.N., Griffith J.L., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63 3 (2003) 1121-1129
105. Mausner-Fainberg K., Luboshits G., Mor A., Maysel-Auslender S., Rubinstein A., Keren G., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197 2 (2008) 829-839
106. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 8A (2006) 89C-94C
107. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
108. Mukai Y., Wang C.Y., Rikitake Y., and Liao J.K. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 292 4 (2007) H1937-1942
109. Nakamura T., Ushiyama C., Hirokawa K., Osada S., Inoue T., Shimada N., et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17 5 (2002) 798-802
110. Narumiya H., Sasaki S., Kuwahara N., Irie H., Kusaba T., Kameyama H., et al. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res 64 2 (2004) 331-336
111. Nawawi H., Osman N.S., Yusoff K., and Khalid B.A. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 35 8 (2003) 479-485
112. Nishikimi T., Koshikawa S., Ishikawa Y., Akimoto K., Inaba C., Ishimura K., et al. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 25 5 (2007) 1053-1063
113. Nishizawa Y., Shoji T., Ishimura E., Inaba M., and Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?. Am J Kidney Dis 38 4 Suppl 1 (2001) S4-S7
114. Nobes C., and Marsh M. Dendritic cells: new roles for Cdc42 and Rac in antigen uptake?. Curr Biol 10 20 (2000) R739-R741
115. O'Donnell M.P., Kasiske B.L., Katz S.A., Schmitz P.G., and Keane W.F. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20 5 (1992) 651-658
116. Ota T., Takamura T., Ando H., Nohara E., Yamashita H., and Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46 6 (2003) 843-851
117. Ozawa Y., and Kobori H. Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. Am J Physiol Renal Physiol 293 1 (2007) F100-109
118. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100 11 (1997) 2671-2679
119. Pai R., Kirschenbaum M.A., and Kamanna V.S. Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells. Kidney Int 48 4 (1995) 1254-1262
120. Parfrey P.S., and Foley R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10 7 (1999) 1606-1615
121. Patel S., Mason R.M., Suzuki J., Imaizumi A., Kamimura T., and Zhang Z. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol 26 4 (2006) 381-387
122. PLANET I (http://clinicaltrials.gov/ct2/show/NCT00296400?term=planet&rank=1).
123. PLANET II (http://clinicaltrials.gov/ct2/show/NCT00296374?term=planet&rank=2).
124. Plenz G.A., Hofnagel O., and Robenek H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation 109 2 (2004) e7-e8 author reply e7-8
125. Porter K.E., Olojugba D.H., Masood I., Pemberton M., Bell P.R., and London N.J. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 28 4 (1998) 695-701
126. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 19 (1998) 1349-1357
127. Rao M., Wong C., Kanetsky P., Girndt M., Stenvinkel P., Reilly M., et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72 5 (2007) 549-556
128. Rayner H.C., Ross-Gilbertson V.L., and Walls J. The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy. Eur J Clin Invest 20 1 (1990) 97-104
129. Romagnani P., Lasagni L., Mazzinghi B., Lazzeri E., and Romagnani S. Pharmacological modulation of stem cell function. Curr Med Chem 14 10 (2007) 1129-1139
130. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80 7 (2000) 1095-1100
131. Ross S.D., Allen I.E., Connelly J.E., Korenblat B.M., Smith M.E., Bishop D., et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 159 15 (1999) 1793-1802
132. Rossouw J.E., Lewis B., and Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med 323 16 (1990) 1112-1119
133. Rovin B.H., and Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43 1 (1993) 218-225
134. Rubin R., Silbiger S., Sablay L., and Neugarten J. Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. Hypertension 23 1 (1994) 92-95
135. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335 14 (1996) 1001-1009
136. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 7 (2006) 2006-2016
137. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 5 (2003) 1050-1065
138. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 17 (2003) 2154-2169
139. Schwarz U., Buzello M., Ritz E., Stein G., Raabe G., Wiest G., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 2 (2000) 218-223
140. Searles C.D., Ide L., Davis M.E., Cai H., and Weber M. Actin cytoskeleton organization and posttranscriptional regulation of endothelial nitric oxide synthase during cell growth. Circ Res 95 5 (2004) 488-495
141. Seliger S.L., Weiss N.S., Gillen D.L., Kestenbaum B., Ball A., Sherrard D.J., et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 1 (2002) 297-304
142. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 64 Suppl 2 (2004) 43-60
143. Shepherd J., Kastelein J.J., Bittner V., Deedwania P., Breazna A., Dobson S., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2 6 (2007) 1131-1139
144. Shepherd J., Vidt D.G., Miller E., Harris S., and Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 107 4 (2007) 433-443
145. Shibata S., Nagase M., and Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17 3 (2006) 754-764
146. Sidaway J.E., Davidson R.G., McTaggart F., Orton T.C., Scott R.C., Smith G.J., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 9 (2004) 2258-2265
147. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 6803 (2000) 538-541
148. 2+ sensitization. Circ Res 91 2 (2002) 83-84
149. Song J., Kost Jr. C.K., and Martin D.S. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc Res 72 3 (2006) 456-463
150. Stoll L.L., McCormick M.L., Denning G.M., and Weintraub N.L. Antioxidant effects of statins. Drugs Today (Barc) 40 12 (2004) 975-990
151. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 4 (2005) 771-778
152. Strippoli G.F., Navaneethan S.D., Johnson D.W., Perkovic V., Pellegrini F., Nicolucci A., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336 7645 (2008) 645-651
153. Sugiyama M., Ohashi M., Takase H., Sato K., Ueda R., and Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 20 4 (2005) 133-136
154. Sun H.Y., Wagener M.M., and Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 8 10 (2008) 2111-2118
155. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 318 Pt 2 (1996) 379-382
156. Suzumura K., Tanaka K., Yasuhara M., and Narita H. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein. Biol Pharm Bull 23 7 (2000) 873-878
157. Sytkowski P.A., Kannel W.B., and D'Agostino R.B. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 322 23 (1990) 1635-1641
158. Tashiro K., Makita Y., Shike T., Shirato I., Sato T., Cynshi O., et al. Detection of cell death of cultured mouse mesangial cells induced by oxidized low-density lipoprotein. Nephron 82 1 (1999) 51-58
159. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 6 2 (2006) 115-120
160. Tonelli M., Isles C., Curhan G.C., Tonkin A., Pfeffer M.A., Shepherd J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 12 (2004) 1557-1563
161. Tonelli M., Moye L., Sacks F.M., Cole T., and Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 6 (2003) 1605-1613
162. Tonelli M., Moye L., Sacks F.M., Kiberd B., and Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 2 (2003) 98-104
163. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 7 (2006) 2034-2047
164. United States Renal Data System. Mortality and cause of death (2007). http://www.usrds.org/2007/ref/H_morte_07.pdf www.usrds.org/2007/ref/H_morte_07.pdf
165. Usui H., Shikata K., Matsuda M., Okada S., Ogawa D., Yamashita T., et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18 2 (2003) 265-272
166. Van Aelst L., and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11 18 (1997) 2295-2322
167. Vaziri N.D., Deng G., and Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14 6 (1999) 1462-1466
168. Vaziri N.D., and Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10 1 (2006) 1-7
169. Vazquez-Perez S., Aragoncillo P., de Las Heras N., Navarro-Cid J., Cediel E., Sanz-Rosa D., et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant 16 Suppl 1 (2001) 40-44
170. Vecchione C., Gentile M.T., Aretini A., Marino G., Poulet R., Maffei A., et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 50 4 (2007) 874-880
171. Verhulst A., D'Haese P.C., and De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15 9 (2004) 2249-2257
172. Verma A., Ranganna K.M., Reddy R.S., Verma M., and Gordon N.F. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 96 9 (2005) 1290-1292
173. Walter D.H., Dimmeler S., and Zeiher A.M. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 4 4 (2004) 385-393
174. Wang C.Y., Liu P.Y., and Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14 1 (2008) 37-44
175. Wang H.R., Li J.J., Huang C.X., and Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353 1-2 (2005) 53-60
176. Wang R., Lagakos S.W., Ware J.H., Hunter D.J., and Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 21 (2007) 2189-2194
177. Wang W., Koka V., and Lan H.Y. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10 1 (2005) 48-56
178. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 3 (2005) 238-248
179. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59 3 (2001) 646-654
180. Weber C., Erl W., Weber K.S., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30 5 (1997) 1212-1217
181. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 6 (2001) 687-692
182. Whaley-Connell A.T., Morris E.M., Rehmer N., Yaghoubian J.C., Wei Y., Hayden M.R., et al. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol 27 1 (2007) 15-23
183. Wiggins R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71 12 (2007) 1205-1214
184. Xu C.B., Stenman E., and Edvinsson L. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol 64 3 (2002) 497-505
185. Xu H., Zeng L., Peng H., Chen S., Jones J., Chew T.L., et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 291 5 (2006) F995-1004
186. Yagi S., Aihara K., Ikeda Y., Sumitomo Y., Yoshida S., Ise T., et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 102 1 (2008) 68-76
187. Yoshimura A., Inui K., Nemoto T., Uda S., Sugenoya Y., Watanabe S., et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9 11 (1998) 2027-2039
188. Zapolska-Downar D., Siennicka A., Kaczmarczyk M., Kolodziej B., and Naruszewicz M. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci 75 11 (2004) 1287-1302
189. Zeng L., Xu H., Chew T.L., Eng E., Sadeghi M.M., Adler S., et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J 19 13 (2005) 1845-1847
190. Zhou M.S., Schuman I.H., Jaimes E.A., and Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 295 1 (2008) F53-59
191. Zoja C., Abbate M., and Remuzzi G. Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens 15 3 (2006) 250-257